{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:55:51Z","timestamp":1790207751984,"version":"4.1.0"},"reference-count":57,"publisher":"American Association for Cancer Research (AACR)","issue":"3","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["CA-111\u223c112-PP-20"],"award-info":[{"award-number":["CA-111\u223c112-PP-20"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["CA-113-PP-17"],"award-info":[{"award-number":["CA-113-PP-17"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["112-2321-B-037-004"],"award-info":[{"award-number":["112-2321-B-037-004"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["114-2634-F-039-001"],"award-info":[{"award-number":["114-2634-F-039-001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Mutations in isocitrate dehydrogenase 1 (IDH1) occur in 10% to 25% of intrahepatic cholangiocarcinoma (iCCA) cases. Despite significantly prolonged progression-free survival, the mutant IDH1 (mIDH1) inhibitor ivosidenib achieved only a 3% response rate in clinical trials, highlighting the need for new therapeutic options for IDH1\u00a0mutation (IDH1mut)\u00a0iCCA. Our in silico analysis demonstrated that IDH1mut and TP53 mutation (TP53mut) were mutually exclusive in iCCA cells and that IDH1mut iCCA cells expressed higher mouse double minute 2 homolog (MDM2) levels than IDH1wt iCCA cells. Chromatin immunoprecipitation quantitative polymerase chain reaction assay showed enrichment of histone-3-lysine-4 tri-methylation (H3K4me3), an indicator of active gene transcription, at the MDM2 promoter in IDH1mut iCCA cells, confirming the data from ENCODE histone-seq. Treatment with a mIDH1 inhibitor reduced 2-hydroxyglutarate (2-HG) levels, enhanced lysine-specific demethylase 5 (KDM5) activity, and attenuated the H3K4me3\/H3K4me1 ratio at the MDM2 promoter, which was accompanied by a reduction in MDM2 expression and an increase in wild-type TP53 (wtTP53) protein levels in IDH1mut iCCA cells. The effect of the mIDH1 inhibitor on MDM2 mRNA levels was reversed by treatment with KDOAM-25 citrate, a pan-KDM5 inhibitor. In addition, MDM2 inhibitors that could block MDM2-mediated wtTP53 degradation selectively induced TP53 reactivation, cell-cycle arrest, and growth inhibition in IDH1mut iCCA cells. The combination of mIDH1 and MDM2 inhibitors synergistically suppressed the proliferation of IDH1mut iCCA cells. Our study delineated a novel mIDH1-MDM2-wtTP53 axis and its potential application for wtTP53 reactivation therapy in IDH1mut iCCA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>IDH1 mutation enhances MDM2 expression by inhibiting KDM5 activity to promote the proliferation of TP53wt iCCA cells. Cotargeting MDM2 and mIDH1 yields a synergistic effect on growth inhibition, providing a new strategy for treating patients with iCCA with IDH1 mutations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0591","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T21:13:19Z","timestamp":1772140399000},"page":"616-629","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mutant Isocitrate Dehydrogenase 1 Sensitizes Intrahepatic Cholangiocarcinoma Cells to MDM2 Inhibitors"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8462-6901","authenticated-orcid":false,"given":"Chien-Tsung","family":"Liu","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02r6fpx29","id-type":"ROR","asserted-by":"publisher"}],"name":"National Health Research Institutes 1 National Institute of Cancer Research, , Tainan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5133-5316","authenticated-orcid":false,"given":"Yung-Yeh","family":"Su","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02r6fpx29","id-type":"ROR","asserted-by":"publisher"}],"name":"National Health Research Institutes 1 National Institute of Cancer Research, , Tainan, Taiwan."},{"id":[{"id":"https:\/\/ror.org\/04zx3rq17","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cheng Kung University Hospital 2 Department of Oncology, , College of Medicine, National Cheng Kung University, Tainan, Taiwan."},{"id":[{"id":"https:\/\/ror.org\/02xmkec90","id-type":"ROR","asserted-by":"publisher"}],"name":"Kaohsiung Medical University Hospital 3 Department of Internal Medicine, , Kaohsiung, Taiwan."},{"id":[{"id":"https:\/\/ror.org\/03gk81f96","id-type":"ROR","asserted-by":"publisher"}],"name":"Kaohsiung Medical University 4 Center for Cancer Research, , Kaohsiung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9292-0055","authenticated-orcid":false,"given":"Nai-Jung","family":"Chiang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02r6fpx29","id-type":"ROR","asserted-by":"publisher"}],"name":"National Health Research Institutes 1 National Institute of Cancer Research, , Tainan, Taiwan."},{"id":[{"id":"https:\/\/ror.org\/03ymy8z76","id-type":"ROR","asserted-by":"publisher"}],"name":"Taipei Veterans General Hospital 5 Department of Oncology, , Taipei, Taiwan."},{"name":"6School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9527-7576","authenticated-orcid":false,"given":"Chien-Feng","family":"Li","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02r6fpx29","id-type":"ROR","asserted-by":"publisher"}],"name":"National Health Research Institutes 1 National Institute of Cancer Research, , Tainan, Taiwan."},{"id":[{"id":"https:\/\/ror.org\/02y2htg06","id-type":"ROR","asserted-by":"publisher"}],"name":"Chi Mei Medical Center 7 Clinical Pathology Department, , Tainan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6325-9250","authenticated-orcid":false,"given":"Yu-Chun","family":"Ma","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02xmkec90","id-type":"ROR","asserted-by":"publisher"}],"name":"Kaohsiung Medical University Hospital 8 Department of Pathology, , , Kaohsiung, Taiwan."},{"id":[{"id":"https:\/\/ror.org\/03gk81f96","id-type":"ROR","asserted-by":"publisher"}],"name":"Kaohsiung Medical University 8 Department of Pathology, , , Kaohsiung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9665-5236","authenticated-orcid":false,"given":"Kung-Chao","family":"Chang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03gk81f96","id-type":"ROR","asserted-by":"publisher"}],"name":"Kaohsiung Medical University 4 Center for Cancer Research, , Kaohsiung, Taiwan."},{"id":[{"id":"https:\/\/ror.org\/04zx3rq17","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cheng Kung University Hospital 9 Department of Pathology, , College of Medicine, National Cheng Kung University, Tainan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5227-5434","authenticated-orcid":false,"given":"Yu-Hsuan","family":"Hung","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02xmkec90","id-type":"ROR","asserted-by":"publisher"}],"name":"Kaohsiung Medical University Hospital 10 Department of Medical Research, , , Kaohsiung, Taiwan."},{"id":[{"id":"https:\/\/ror.org\/03gk81f96","id-type":"ROR","asserted-by":"publisher"}],"name":"Kaohsiung Medical University 10 Department of Medical Research, , , Kaohsiung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4860-5415","authenticated-orcid":false,"given":"Wen-Chun","family":"Hung","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02r6fpx29","id-type":"ROR","asserted-by":"publisher"}],"name":"National Health Research Institutes 1 National Institute of Cancer Research, , Tainan, Taiwan."},{"name":"11Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3250-7167","authenticated-orcid":false,"given":"Li-Tzong","family":"Chen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02r6fpx29","id-type":"ROR","asserted-by":"publisher"}],"name":"National Health Research Institutes 1 National Institute of Cancer Research, , Tainan, Taiwan."},{"id":[{"id":"https:\/\/ror.org\/04zx3rq17","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cheng Kung University Hospital 2 Department of Oncology, , College of Medicine, National Cheng Kung University, Tainan, Taiwan."},{"id":[{"id":"https:\/\/ror.org\/02xmkec90","id-type":"ROR","asserted-by":"publisher"}],"name":"Kaohsiung Medical University Hospital 3 Department of Internal Medicine, , Kaohsiung, Taiwan."},{"id":[{"id":"https:\/\/ror.org\/03gk81f96","id-type":"ROR","asserted-by":"publisher"}],"name":"Kaohsiung Medical University 4 Center for Cancer Research, , Kaohsiung, Taiwan."},{"name":"12Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"2026032002100351400_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026032002100351400_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39 Suppl 1","author":"Kendall","year":"2019","journal-title":"Liver Int"},{"key":"2026032002100351400_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12253-018-0491-8","article-title":"Cholangiocarcinoma: classification, histopathology and molecular carcinogenesis","volume":"26","author":"Lendvai","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"2026032002100351400_bib4","article-title":"An interactive website for SEER cancer statistics","volume-title":"Surveillance Research Program","author":"SEER*Explorer","year":"2024"},{"key":"2026032002100351400_bib5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41416-020-0987-3","article-title":"Current and novel therapeutic opportunities for systemic therapy in biliary cancer","volume":"123","author":"Marin","year":"2020","journal-title":"Br J Cancer"},{"key":"2026032002100351400_bib6","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"2026032002100351400_bib7","first-page":"PO.18.00414","article-title":"Intrahepatic cholangiocarcinoma: genomic heterogeneity between Eastern and Western patients","volume":"4","author":"Cao","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"2026032002100351400_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026032002100351400_bib9","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nature09132","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"465","author":"Dang","year":"2010","journal-title":"Nature"},{"key":"2026032002100351400_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.trecan.2017.12.005","article-title":"Metabolism, activity, and targeting of D- and L-2-hydroxyglutarates","volume":"4","author":"Ye","year":"2018","journal-title":"Trends Cancer"},{"key":"2026032002100351400_bib11","doi-asserted-by":"crossref","first-page":"982424","DOI":"10.3389\/fphar.2022.982424","article-title":"Recent advances of IDH1 mutant inhibitor in cancer therapy","volume":"13","author":"Tian","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026032002100351400_bib12","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00280-023-04633-5","article-title":"Pharmacokinetics\/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study","volume":"93","author":"Fan","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026032002100351400_bib13","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026032002100351400_bib14","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2026032002100351400_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"2026032002100351400_bib16","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov"},{"key":"2026032002100351400_bib17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-018-0251-7","article-title":"Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations","volume":"559","author":"Intlekofer","year":"2018","journal-title":"Nature"},{"key":"2026032002100351400_bib18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1158\/2159-8290.CD-21-1661","article-title":"Disabling uncompetitive inhibition of oncogenic IDH mutations drives acquired resistance","volume":"13","author":"Lyu","year":"2023","journal-title":"Cancer Discov"},{"key":"2026032002100351400_bib19","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res"},{"key":"2026032002100351400_bib20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2026032002100351400_bib21","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"2026032002100351400_bib22","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2026032002100351400_bib23","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant graphics for data analysis","author":"Wickham","year":"2016"},{"key":"2026032002100351400_bib24","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2024"},{"key":"2026032002100351400_bib25","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"2026032002100351400_bib26","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J Hepatol"},{"key":"2026032002100351400_bib27","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"2026032002100351400_bib28","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"2026032002100351400_bib29","doi-asserted-by":"crossref","first-page":"18775","DOI":"10.1038\/s41598-022-22543-z","article-title":"Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma","volume":"12","author":"Rimini","year":"2022","journal-title":"Sci Rep"},{"key":"2026032002100351400_bib30","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"key":"2026032002100351400_bib31","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41416-022-01932-1","article-title":"Precision oncology for intrahepatic cholangiocarcinoma in clinical practice","volume":"127","author":"Tomczak","year":"2022","journal-title":"Br J Cancer"},{"key":"2026032002100351400_bib32","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"2026032002100351400_bib33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"2026032002100351400_bib34","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/jmcb\/mjab047","article-title":"Deciphering the PTM codes of the tumor suppressor p53","volume":"13","author":"Wen","year":"2022","journal-title":"J Mol Cell Biol"},{"key":"2026032002100351400_bib35","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1158\/2159-8290.CD-22-0825","article-title":"(R)-2-Hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers","volume":"13","author":"Gunn","year":"2023","journal-title":"Cancer Discov"},{"key":"2026032002100351400_bib36","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41586-020-2363-0","article-title":"Oncometabolites suppress DNA repair by disrupting local chromatin signalling","volume":"582","author":"Sulkowski","year":"2020","journal-title":"Nature"},{"key":"2026032002100351400_bib37","doi-asserted-by":"crossref","first-page":"D56","DOI":"10.1093\/nar\/gks1172","article-title":"ENCODE data in the UCSC Genome Browser: year 5 update","volume":"41","author":"Rosenbloom","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2026032002100351400_bib38","doi-asserted-by":"crossref","first-page":"D493","DOI":"10.1093\/nar\/gkh103","article-title":"The UCSC Table Browser data retrieval tool","volume":"32","author":"Karolchik","year":"2004","journal-title":"Nucleic Acids Res"},{"key":"2026032002100351400_bib39","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/bioinformatics\/btt637","article-title":"Track data hubs enable visualization of user-defined genome-wide annotations on the UCSC Genome Browser","volume":"30","author":"Raney","year":"2014","journal-title":"Bioinformatics"},{"key":"2026032002100351400_bib40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cell.2007.08.016","article-title":"Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4","volume":"131","author":"Vermeulen","year":"2007","journal-title":"Cell"},{"key":"2026032002100351400_bib41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41586-023-05780-8","article-title":"H3K4me3 regulates RNA polymerase II promoter-proximal pause-release","volume":"615","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"2026032002100351400_bib42","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"2026032002100351400_bib43","doi-asserted-by":"crossref","first-page":"a026245","DOI":"10.1101\/cshperspect.a026245","article-title":"Targeting the MDM2-p53 protein-protein interaction for new cancer therapy: progress and challenges","volume":"7","author":"Wang","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026032002100351400_bib44","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.bbrc.2007.01.089","article-title":"A p53-type response element in the GDF15 promoter confers high specificity for p53 activation","volume":"354","author":"Osada","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"2026032002100351400_bib45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: mechanisms, structures, and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026032002100351400_bib46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-022-01314-3","article-title":"Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials","volume":"15","author":"Zhu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026032002100351400_bib47","doi-asserted-by":"crossref","first-page":"114334","DOI":"10.1016\/j.ejmech.2022.114334","article-title":"Small-molecule MDM2 inhibitors in clinical trials for cancer therapy","volume":"236","author":"Wang","year":"2022","journal-title":"Eur J Med Chem"},{"key":"2026032002100351400_bib48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/OTT.S440979","article-title":"Efficacy and safety of the MDM2-p53 antagonist Brigimadlin (BI 907828) in patients with advanced biliary tract cancer: a case series","volume":"17","author":"Yamamoto","year":"2024","journal-title":"Onco Targets Ther"},{"key":"2026032002100351400_bib49","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/1078-0432.CCR-21-1295","article-title":"Results from a first-in-human phase I study of Siremadlin (HDM201) in patients with advanced wild-type TP53 solid tumors and acute leukemia","volume":"28","author":"Stein","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026032002100351400_bib50","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00280-018-3534-7","article-title":"Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML","volume":"81","author":"Blotner","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026032002100351400_bib51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.exphem.2013.11.012","article-title":"Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis","volume":"42","author":"Iancu-Rubin","year":"2014","journal-title":"Exp Hematol"},{"key":"2026032002100351400_bib52","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12943-024-02011-0","article-title":"KDM5 family as therapeutic targets in breast cancer: pathogenesis and therapeutic opportunities and challenges","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer"},{"key":"2026032002100351400_bib53","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The Cancer Genome Atlas Pan-Cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat Genet"},{"key":"2026032002100351400_bib54","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nat Genet"},{"key":"2026032002100351400_bib55","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ng.2813","article-title":"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas","volume":"45","author":"Jiao","year":"2013","journal-title":"Nat Genet"},{"key":"2026032002100351400_bib56","doi-asserted-by":"crossref","first-page":"6087","DOI":"10.1038\/ncomms7087","article-title":"Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma","volume":"6","author":"Sia","year":"2015","journal-title":"Nat Commun"},{"key":"2026032002100351400_bib57","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMp1607591","article-title":"Toward a shared vision for cancer genomic data","volume":"375","author":"Grossman","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0591\/3743551\/crc-25-0591.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/616\/3748890\/crc-25-0591.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/3\/616\/3748890\/crc-25-0591.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T06:10:24Z","timestamp":1773987024000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/3\/616\/775494\/Mutant-Isocitrate-Dehydrogenase-1-Sensitizes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0591","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.31818317","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31818308","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31818329","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31818320","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31818311","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31818332","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31818323","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31818326","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.31818314","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8372975","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}